Compare · AFIB vs LIVN
AFIB vs LIVN
Side-by-side comparison of Acutus Medical Inc. (AFIB) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AFIB and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.32B, about 77.7x AFIB ($55.6M).
- LIVN has hit the wire 1 time in the past 4 weeks while AFIB has been quiet.
- LIVN has more recent analyst coverage (21 ratings vs 7 for AFIB).
- Company
- Acutus Medical Inc.
- LivaNova PLC
- Price
- $0.09-28.15%
- $77.61-1.17%
- Market cap
- $55.6M
- $4.32B
- 1M return
- -
- -0.29%
- 1Y return
- -
- +43.34%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 1
- Recent ratings
- 7
- 21
Acutus Medical Inc.
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based in Carlsbad, California.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest AFIB
- SEC Form 10-K filed by Acutus Medical Inc.
- Acutus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Acutus Medical Reports Full Year 2024 Financial Results
- SEC Form 4 filed by Director by deputization Flynn James E
- Amendment: SEC Form SCHEDULE 13D/A filed by Acutus Medical Inc.
- SEC Form 15-15D filed by Acutus Medical Inc.
- SEC Form EFFECT filed by Acutus Medical Inc.
- SEC Form EFFECT filed by Acutus Medical Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Acutus Medical Inc.
- SEC Form S-8 POS filed by Acutus Medical Inc.
Latest LIVN
- Barclays initiated coverage on LivaNova with a new price target
- LivaNova to Announce Third-Quarter 2026 Results
- SEC Form 4 filed by Chief Legal Officer Liddy Anne M.
- Director Bianchi Francesco sold $273,032 worth of Ordinary Shares (3,500 units at $78.01), decreasing direct ownership by 44% to 4,434 units (SEC Form 4)
- Director Story Brooke sold $187,270 worth of Ordinary Shares (2,300 units at $81.42), decreasing direct ownership by 23% to 7,488 units (SEC Form 4)
- LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
- Director Bianchi Francesco sold $131,538 worth of Ordinary Shares (1,650 units at $79.72), decreasing direct ownership by 17% to 7,934 units (SEC Form 4)
- SEC Form 3 filed by new insider Liddy Anne M.
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC